Hidradenitis suppurativa: A comprehensive review

Ali Alikhan, a Peter J. Lynch, MD, b and Daniel B. Eisen, MD b
Sacramento, California

Hidradenitis suppurativa, also known as acne inversa, is a chronic, often debilitating disease primarily affecting the axillae, perineum, and inframammary regions. Prevalence rates of up to 4% have been estimated. Our understanding of the disease has changed over time. It is now considered a disease of follicular occlusion rather than an inflammatory or infectious process of the apocrine glands. Clinically, the disease often presents with tender subcutaneous nodules beginning around puberty. The nodules may spontaneously rupture or coalesce, forming painful, deep dermal abscesses. Eventually, fibrosis and the formation of extensive sinus tracts may result. The location of the lesions may lead to social embarrassment and the failure to seek medical treatment. Therapies in the past have consisted of long-term antibiotics, antiandrogens, and surgery. New treatments like tumor necrosis factor—alpha inhibitors have given clinicians more options against this difficult disease. (J Am Acad Dermatol 2009;60:539-61.)

Learning objectives: After completing this learning activity, participants should be able to describe the clinical presentation, demographics, and prevalence of hidradenitis suppurativa, be familiar with current controversies regarding the pathogenesis of this complex, and be able to discuss potential treatments and their outcomes.

Key words: acne inversa; etanercept; hidradenitis suppurativa; infliximab; Verneuil disease.

Key points
• HS is a chronic, recurrent, inflammatory disease presenting as painful subcutaneous nodules
• Double comedones, deep sinus tracts, and abscesses are characteristic for HS
• A diagnosis of HS is made clinically without the use of laboratory tests

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, inflammatory disease, initially presenting as tender subcutaneous nodules. These lesions may spontaneously rupture or coalesce to form deep dermal, exquisitely painful abscesses.1 The abscesses have typically been described as being deep and rounded without central necrosis or pointing (though this may sometimes occur), and they often exude a purulent drainage.1,2 The inflammatory abscesses ultimately heal, producing fibrosis, dermal contractures, and induration of the skin.3 The disease is insidious, typically developing in otherwise healthy postpubertal males and females.4

Another lesion typical in HS is the double comedone, a blackhead with multiple apertures that communicate below the skin.5 These abnormal comedones have been reported on flexural surfaces of children, and may be the precursors of HS lesions.6 The disease process is thought to begin with occlusion of hair follicles. The occluded follicles subsequently rupture and reepithelialize, resulting in sinus tracts that can house foreign material and bacteria.5 Over time, these tracts can coalesce into large regions of subcutaneous honeycombing.7 They can potentially dissect into deep structures including muscle, fascia, lymph nodes, the urethra, and the
bowels. They release a serous to purulent malodorous discharge, resulting in both soiling of clothes and social embarrassment. Ulceration of the skin has also been described with chronic HS. The ulcers characteristically present with rolled, boggy, ragged edges and clean granulating bases. Like most diseases, especially its analogue acne conglobata, the severity varies considerably.

Early symptoms and signs of HS are burning, pruritus, local warmth, hyperhidrosis, and pain. HS may be divided into acute and chronic forms. Acute HS presents with a few deep-seated nodules, which may coalesce developing into cord-like red-to-bluish red structures. Chronic HS is characterized by multiple abscesses, internetworking sinus tracts, foul exudate from draining sinuses, inflammation in the dermis, both atrophic and hypertrophic scars, ulceration, and infection which may extend deep into the fascia.

The diagnosis of HS is made clinically, and biopsies are not routinely taken. There is no confirmatory test for HS. Criteria for diagnosis vary widely but typically include chronicity, recurrence of disease, failure to completely clear with antibiotics, characteristic multifocal lesion distribution, sinus formation, scarring and dermal contracture, presence of double comedones, multiple open comedones, nodules, papules, tenderness of lesions, and malodorous discharge.

DEMOGRAPHICS

Key points

- HS tends to begin in the second or third decades of life
- Females are more likely to develop HS
- Recent studies suggest a prevalence of about 1%

HS typically occurs after puberty, with average age of onset in the second or third decades of life. Onset after menopause is rare. Isolated case reports have described HS in prepubertal subjects, but these are associated with premature adrenarche. HS prevalence may diminish over time. A recent study showed that prevalence among those 55 years of age and older was significantly lower than in younger age groups (0.5% vs 1.4%).

A large Danish study estimated 1-year prevalence at 1.0% based on subject recollection only, and point prevalence at 4.1% based on objective findings. The point prevalence was based on a younger adult population and may, therefore, overestimate the true prevalence of HS. A recent case control study based on a representative portion of the French population (n = 10,000) estimated prevalence at 1%. Other studies have estimated various prevalence rates ranging from 0.00033% to 4%. HS appears to be significantly more common among females. HS researchers generally accept this, but many authors have argued that certain locations appear to have sexual predilection. Perianal HS, for instance, seems to affect males more than females. Some authors have suggested a higher prevalence of HS among African Americans. This has not been substantiated by any studies examining racial predilection.

CLINICAL PRESENTATION

Key points

- HS most typically occurs in the axillary, inguinal, perianal, perineal, mammary, and inframammary regions
- The distribution pattern corresponds with the "milk line" distribution of apocrine-related mammary tissue in mammals
- The most commonly affected site is the axilla
- Perianal HS is associated with more debilitating outcomes

HS is characterized initially by the presence of tender subcutaneous nodules. With time, the nodules may rupture, resulting in painful, deep dermal abscesses. The lesions may be rounded, but, unlike furuncles, do not usually exhibit pointing. After rupture, the lesions often extrude a purulent, foul-smelling discharge. As the disease process continues, fibrosis, dermal contractures, and induration of the skin occur. The presence of double comedones is typical of the disease. HS develops gradually in postpubertal males and females who are otherwise healthy.

HS lesions occur most frequently in the intertriginous apocrine gland-bearing areas of the axillary, inguinal, perianal, perineal, mammary, inframammary, buttock, pubic, chest, scalp, retroauricular, and eyelid areas. This distribution pattern corresponds for the most part with the "milk line" distribution of apocrine-related mammary tissue in mammals. The sites affected in HS correspond not only to the location of apocrine glands in the body but also to that of terminal hair follicles dependent on low androgen concentrations. One study with 388 HS patients demonstrated axillary involvement in 278 patients (72%), perianal involvement in 125 patients (32%), groin involvement in 92 patients (24%), and mammary involvement in 32 patients (8%). Similar rates were seen in a study by Barth et al. Perineal HS is associated with a much higher rate of recurrence (74% in one study) and more
debilitating outcomes than axillary HS. Lesions often initially occur in the axillae and anogenital regions, but once the disease advances, new lesions develop in areas of friction, including the submammary region (Fig 1), the nape of the neck, the waistband area, and the inner thighs.

Patients with anogenital HS may also have disease in the anal canal (30 of 132 patients in one study). HS in the anal canal lies superficial to the internal sphincter and begins in the lower two-thirds of the canal, distal to the dentate line (the transition zone from columnar epithelium to squamous epithelium). This corresponds with the distribution of apocrine glands and hair follicles in the anal canal. If lesions are seen proximal to this area, disorders such as Crohn disease (CD) or a fistulous abscess should be considered.

**CLINICAL STAGING**

**Key points**
- Hurley’s staging system is simple and relies on the subjective extent of diseased tissue
- The Sartorius system is more sophisticated than Hurley’s and is likely to supplant it as a means for conducting clinical trials

One of the first staging systems for HS was proposed by Hurley (Table I). Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses (Figs 2, 3, and 4). It has been used as a basis for clinical trials in the past and is a useful basis to approach therapy for patients. Its advantage is its simplicity. However, Sartorius et al have suggested that the Hurley system is not sophisticated enough to assess treatment effects in clinical studies. They suggest a system that incorporates the involved anatomic regions, number and types of lesions, distance between lesions, and the presence of normal skin in between lesions. Points are accumulated in each of the mentioned categories and added to give both a regional and total score. In addition, the authors suggest adding a visual analog scale for pain or using the dermatology life quality index (DLQI) when assessing HS. This system will likely be the basis of many future clinical trials.

**DIFFERENTIAL DIAGNOSIS**

**Key points**
- The differential diagnosis for HS is extensive, but can easily be differentiated from other diseases by the age of onset and characteristic locations of the lesions

The differential diagnosis for HS is extensive (Table II) but is usually easy to discern from other diseases. HS can be differentiated from other diseases by the appearance of the lesions, postpubertal age of onset, characteristic locations, resistance to antibiotics, recovery of multiple species (rather than a single species) of bacteria on culture, absence of fever, and the lack of significant laboratory findings (Fig 5). An important feature distinguishing almost all of these other diseases from HS is the specific histology (often with special stains for organisms) in the non-HS diseases.

---

**Table I. Hurley staging system for hidradenitis suppurativa**

<table>
<thead>
<tr>
<th>Hurley stage</th>
<th>Extent of disease in tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Abscess formation (single or multiple) without sinus tracts and cicatrization</td>
</tr>
<tr>
<td>II</td>
<td>One or more widely separated recurrent abscesses with tract formation and scars</td>
</tr>
<tr>
<td>III</td>
<td>Multiple interconnected tracts and abscesses throughout an entire area</td>
</tr>
</tbody>
</table>

**Fig 1.** Inflammatory papules and nodules in the inframammary area typical of hidradenitis suppurativa. (Courtesy of Michael S. Wong, MD, Department of Plastic Surgery, University of California–Davis, Sacramento, CA.)

**Fig 2.** Hurley stage I—single or multiple abscesses without cicatrization and sinus tracts.
ETIOPATHOGENESIS

Key points

- Long thought to be a disorder of apocrine origin, it is now thought to be caused by follicular occlusion
- Families with autosomal dominance type inheritance have been reported
- Hyperandrogenism likely does not play a role in HS
- Bacteria are probably secondary colonizers, which may exacerbate HS, but they are not the primary etiologic agents
- Poor hygiene does not cause HS
- Some investigators postulate that there may be an underlying immunologic aberration involved in the pathogenesis of HS; more work needs to be done in this field before any conclusions can be made
- Smoking and obesity are not primary causes of HS but are strongly associated with the disease and may exacerbate it

Follicular and glandular factors

Early studies implicating apocrine glands. Our understanding of the pathogenesis of HS has changed over time. It was originally described by the French physician, Velpeau, in 1839, as indicated by Slade et al.1

He wrote about a patient with circumscribed inflammation with superficial abscesses affecting the skin of the axilla, mammary, and perianal areas.1 In 1854, Verneuil reported on a series of patients with similar lesions in the axilla and groin, and hypothesized that the primary cause was purulent inflammation of the sweat glands.1,30 He named the disease HS. This became the accepted theory for more than a century. In 1922, Schiefferdecker40 classified sweat glands as eccrine and apocrine. In 1939, Brunsting,11 who completed a study using histologic specimens from 16 patients, suggested that the apocrine gland was to blame for the disease.11 He suggested that the earliest cellular reaction seen in HS was an inflammatory reaction in the subcutis, localized to the lumen of the apocrine gland and neighboring periglandular connective tissue. He stated that these findings supported an earlier opinion that the disease starts with an infectious process that enters the hair follicle and excretory tubule of the apocrine glands, but does not cause inflammation until the gland itself is reached.11 The infection then was theorized to spread in the subcutis by way of lymph channels.11

In 1955, Shelley and Cahn41 attempted to simulate HS by applying belladonna adhesive tape continuously for 2 weeks to manually depilated axillary skin.41 Three of the 12 study subjects developed deep, tender nodules similar to HS lesions.41 Histologically, keratinous plugging of the apocrine sweat duct, dilatation of the duct, and severe inflammatory changes limited to the apocrine gland, but does not cause inflammation until the gland itself is reached.11 The infection then was theorized to spread in the subcutis by way of lymph channels.11

In Figure 3, Hurley stage II—one or more widely separated recurrent abscesses, with tract formation and scars.

In Figure 4, Hurley stage III—multiple interconnected tracts and abscesses throughout an entire area.

Table II. Differential diagnosis of hidradenitis suppurativa

<table>
<thead>
<tr>
<th>Early lesions</th>
<th>Late lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acne</td>
<td>Actinomycosis</td>
</tr>
<tr>
<td>Carbuncles</td>
<td>Anal fistula</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>Cat scratch disease</td>
</tr>
<tr>
<td>Cutaneous blastomycosis</td>
<td>Crohn disease</td>
</tr>
<tr>
<td>Dermoid cyst</td>
<td>Granuloma inguinale</td>
</tr>
<tr>
<td>Erysipelas</td>
<td>Ischiorectal abscess</td>
</tr>
<tr>
<td>Furuncles</td>
<td>Lymphphogranuloma venereum</td>
</tr>
<tr>
<td>Inflamed epidermoid cysts</td>
<td>Nocardia infection</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>Noduloulcerative syphilis</td>
</tr>
<tr>
<td>Perirectal abscess</td>
<td>Pilonidal disease</td>
</tr>
<tr>
<td>Pilonidal cyst</td>
<td>Tuberculous abscess</td>
</tr>
</tbody>
</table>

Tularemia
objections to the methodology of the study, and only a minority of treated patients who experienced symptoms, the study’s conclusions became dogma. Alternatives from the conclusions of Shelly et al developed over several decades.\textsuperscript{3,43}

**Evidence for follicular-based pathogenesis.** In 1958, Anderson and Dockerty\textsuperscript{3} examined 261 histologic sections from 64 HS patients; they noted a lack of focal inflammation within the apocrine glands. Inflammation of apocrine glands occurred only in

---

**EVALUATION ALGORITHM**

1) Is there more than a single inflamed lesion?
2) Is the course chronic with new and recurrent lesions?
3) Are the lesions bilateral?
4) Are the lesions located primarily in the milk line?

The answer is “no” to one or more of these four questions

I & D; get culture for bacteria, fungi and mycobacterial microbes

The answer is “yes” to all four questions

Culture is sterile or more than a single species is recovered

Culture is positive for a single species only

Is there a history of GI symptoms and signs?

Diagnosis is: INFECTION

No

Yes

Biopsy; get GI evaluation

Biopsy and GI evaluation are compatible with a diagnosis of CROHN DISEASE

No

Yes

Treat or refer for treatment

A clinical diagnosis of HIDRADENITIS SUPPURATIVA is established

No

No

Proceed to treatment

**Fig 5.** Algorithm for the evaluation of a patient in whom the diagnosis of hidradenitis suppurativa is being considered. This algorithm is based upon expert opinion and has not been scientifically validated.
the presence of widespread inflammation, affecting the eccrine glands, hair follicles, sebaceous glands, and small blood vessels. The authors concluded that inflammation of apocrine glands is not essential to HS pathogenesis, occurring only secondarily. Twenty years later, Morgan and Hughes demonstrated no difference in size or density of apocrine glands in HS subjects compared with those of controls.

Despite its prominent role in acne pathogenesis, dysfunctional sebum excretion appears to be unimportant in HS. A study demonstrated similar frequency, density, and pattern of active sebaceous glands in HS patients and control subjects. Furthermore, no significant axillary, genitofemoral, or facial seborrhea was described.

In 1990, Yu and Cook published a histologic study that examined axillary skin specimens from HS patients. They found abnormal, dilated hair follicles in 10 of 12 HS subjects and stratified squamous epithelium-lined cysts or sinuses in the dermis. Laminated keratin was present in all cysts, and half contained hair shafts, suggesting that the cysts were, indeed, dilated hair follicles. Similar dilation of hair follicles with small cysts was found in a recent study in which atypical comedones, similar to those seen in patients with HS, were biopsied. Apocrine gland inflammation was described in four subjects, but only in the background of extensive inflammation involving eccrine glands, hair follicles, and other local structures. They concluded that the abnormal, dilated hair follicles were more prevalent than apocrine inflammation, suggesting that apocrinitis occurs as a secondary phenomenon. In 1995, Attanoos et al described similar findings to those of Yu and Cook in their study of 118 specimens of varying disease duration. A year later, Jemec and Hansen performed a study confirming follicular involvement as the predominant feature in most HS lesions. In fact, in their study, secondary eccrine involvement was more prevalent than secondary apocrine involvement (25% vs 12%). Similar findings were also noted by Heller et al in a 2002 histologic study of HS.

With the results of the previously described studies, many now feel that HS lesions begin with follicular plugging. This plugging presumably results in occlusion and dilation of the pilosebaceous unit, with subsequent rupture (Fig 6). Extrusion of follicular contents, primarily consisting of corneocytes, bacteria, sebum products, and hair into the dermis produce a chemotactic inflammatory response. The resulting influx of neutrophils, lymphocytes, and histiocytes lead to abscess formation. This facilitates infection with further suppuration. With recurrence, sinuous, fistulous, tracts evolve.

There are several theories as to how follicular plugging may occur. The plugging may be caused by hyper- or parakeratosis or anatomically abnormal follicles with inadequate outlets to the surface. The potential role of abnormal hair follicles, hormones, obesity, and environmental factors will be explored individually later in this section.

An interesting study by Jemec and Gniadecka used ultrasonography to look at hair follicles of patients with HS. He found that even areas of clinically uninvolved skin had follicles with distorted shapes and larger deep diameters; the superficial diameter appeared normal. However, quantitatively, this distorted shape with an increase in width difference was statistically significant only in the genitofemoral paralesional follicles, not in axillary ones. Mean axillary and genitofemoral skin thickness and follicular area were also increased in HS patients, though they were statistically significant only in the axillary skin. Jemec and Gniadecka suggest that increased dermal thickness, resulting in alteration of cutaneous mechanical properties, could be a physical factor in HS development or simply the result of chronic inflammation.

Kurzen et al have suggested that suboptimal biomechanics of keratin found in HS lesions may lead to microtears in the hair follicles. They theorize that this may be the primary event in the disease process. They further speculate that HS might also be caused by an abnormality in inflammatory signals. Sinus tracts were proposed to result from an aberrant epidermal response to injury propagated by stem cell–like cells originating in hair follicles.

Larralde et al reported 40 pediatric and adolescent patients with flexural comedones. Biopsies from six patients revealed follicular plugging and infundibular dilation. It was proposed that this entity could be a precursor to HS. As the authors noted, further follow-up and larger studies are necessary before drawing conclusions.

Nonfollicular-based theories. Some believe that apocrine glands may yet be proven to play a role in HS lesions. Revuz suggests that an abnormal secretion—either the excess or absence of—could be causing an effect on the acro infundibulum, distal from the gland itself, and therefore was not detected by previous histopathology studies.

Kurokawa proposes that sinus tract formation is an early feature of HS, not a late one. In fact, he suggests that they arise not from hair follicles but rather from invaginations of the epidermis. These invaginations form infundibulum-like epithelium that protrudes into the reticular dermis as cysts. Resident bacteria, such as CNS can cause adherence
of the epithelium. Therefore, CNS may cause adherence of the epidermis in the adjacent, closed serrated tissue of intertriginous areas, leading to the formation of cysts and HS lesions.

**Genetic factors.** One form of HS may have an AD mode of transmission. Fitzsimmons and Guilbert found that 34% of first-degree relatives of probands also had HS. Both males and females were affected via vertical transmission through several generations, consistent with AD inheritance. Many of the first-degree relatives were under 20 years of age during the study. It was hypothesized that if the study subjects were followed for longer periods of time, more of them might develop the disease, bringing the percentage of those affected closer to 50%. In support of this supposition, Von der Worth et al restudied these same families 15 years later and did note that additional cases of HS had developed. However, the transmission rate was still less than the 50% rate associated with AD inheritance. They suggested this might be because of their rigid disease definition, incomplete penetrance, and hormonal influences. Jemec suggested that increased familial incidence of HS may be caused by a genetically determined end-organ malfunction that is manifested only under certain conditions.

Genetics studies in a large four-generation Chinese family with HS indicate a locus for the disease on chromosome 1p21.1-1q25.3. However, because of the considerable size of this region, a specific gene was not identified. Genetics studies in a large four-generation Chinese family with HS indicate a locus for the disease on chromosome 1p21.1-1q25.3. However, because of the considerable size of this region, a specific gene was not identified. However, Barth et al found that the increased free androgen index was secondary to low sex hormone binding globulin levels. Sex hormone binding globulin can be decreased in those with excess body weight, and this factor was not corrected for in previous studies. Barth et al compared females with HS to body mass index-matched controls. Both groups were also matched for hirsutism, which was previously thought to be related to higher androgen levels. No difference was observed in plasma testosterone and dehydroepiandrosterone. Another study performed by Barth and Kealey examined histologically isolated apocrine glands from five female patients with HS and age-matched controls. They found that androgen interconverting enzymes in the HS samples were either decreased or were not different from normal controls. These results argue against a basis for hyperandrogenism in women with HS, or exaggerated activity of end-organ androgen interconverting enzymes.

Similarly, Jemec et al found no difference in androgenization (acne, hirsutism, and irregular menstrual periods) between 70 female HS patients and 100 healthy controls. However, Harrison et al demonstrated an association between the absence of a premenstrual HS flare (43% of women in their study) and irregular or anovulatory menstrual cycles, obesity, and acne vulgaris. These patients had lower progesterone levels, higher testosterone levels, higher androstenedione levels, and higher androgen indexes than controls and HS-afflicted women with premenstrual flares. The authors offered no satisfactory explanation for these findings. Further evidence against a role for hyperandrogenism in HS is the notable female predominance. This is quite unlike the situation in acne where a role for androgenic influence correlates well with both an increased incidence and greater severity in males.

Some researchers also suggest that progestogens in oral contraceptives (OCs) play a role in the development of HS. A temporal association between OC initiation and HS onset was shown in
seven patients, most resolving after discontinuation or substitution to a higher estrogen to progestogen ratio OC. However, other studies have not found an association between HS and OCs. Interestingly, case reports of two HS patients noted marked improvement in lesions, tenderness, and joint range of motion during pregnancy; in one patient, disease relapsed after delivery (the other was lost to follow-up). HS may decline substantially following menopause, also suggesting a hormonal role.

Harrison et al demonstrated significantly greater prolactin and thyroid-stimulating hormone responses following thyrotropin-releasing hormone stimulation in HS patients. Increased estrogen activity, which can occur in androgen excess, may result in higher prolactin and thyroid-stimulating hormone stores.

**Bacterial factors.** Many researchers have suggested that bacterial infection is an important factor in HS pathogenesis. Studies on HS bacteriology have produced conflicting results, depending on methods used to obtain bacteria. In older studies, bacteria were collected from the surfaces of HS lesions. Gram-negative bacteria, such as Escherichia coli, Klebsiella, and Proteus, may be more common in perineal HS. Chlamydia trachomatis was demonstrated serologically in 6 of 7 patients with perineal HS but was absent in the pus of examined lesions. The fact that so many bacterial species were recovered in these studies and that no single species was dominant suggests that bacteria found on the surface of lesions are secondary colonizers rather than etiologic agents in HS.

A study involving an aspiration technique to sample deeper parts of early HS lesions demonstrated negative cultures in 51% of cases, suggesting that HS is primarily a disease of the follicular epithelium that is secondarily colonized and infected by bacteria. The most common bacteria found were Staphylococcus epidermidis and S aureus. Those with S aureus had significantly shorter disease duration. Therefore, S aureus may be involved only in early stages of disease, producing early anatomic changes in the hair follicle.

One study circumvented the issues of contamination from superficial colonizing bacteria through the use of a carbon dioxide laser method to ablate HS tissue in a stepwise manner, collecting bacteria from three subsequently deeper levels. All patients had positive cultures in at least one of the three levels examined, with elevated bacterial counts in the deep cultures. Though this is debatable, bacteria recovered from HS lesions more likely play a secondary, rather than a primary, role in HS. Environmental factors. A retrospective study of 45 patients showed that 10 had a history of mechanical irritation before onset of the disease. The mentioned causes of trauma were diverse, and ranged from shaving to friction from a prosthesis. Mustafa et al reported several patients whose HS was worsened by the use of antiperspirants. Some authors have suggested that antiperspirants could exacerbate HS by causing an occlusive film over axillary skin. Antiperspirants may also trigger HS via chemical irritation inducing poral closure or altering axillary flora. Edlich et al also suggested that using safety razors may increase HS susceptibility, enhancing bacterial access via transection of the follicular infundibulum.

A retrospective study by Morgan and Leicester comparing 40 HS patients with 40 age-matched controls demonstrated no significant differences in shaving, chemical depilatories, deodorants, and talcum powder application in both axillary and inguinal regions, as previously suggested. Older papers suggest that poor hygiene, dyspepsia, constipation, and hemorrhoids could potentially contribute to HS; none of these causes have been proven. Obesity may serve to retain sweat, possibly aggravating the role of perspiration as an irritant in HS.

**Host defense factors.** Because of the chronic, relapsing nature of HS, defects in host defense mechanisms are postulated etiologic factors. However, Dvorak et al concluded that host defense mechanisms are intact in HS patients. This group of investigators demonstrated that there were no abnormalities in granulocyte function (chemotaxis, phagocytosis, and intracellular killing of ingested bacteria), cell-mediated immunity studies, or immunoglobulin levels. Hemolytic complement levels were elevated in all subjects, indicating that inflammation may play a primary role in HS. A more recent study demonstrated significant increases in neutrophilic generation of free oxygen radicals after stimulation with phorbol myristate acetate, a protein kinase C activator. This suggests that a neutrophilic functional defect may play a pathogenic role in HS.
Giamarellos-Bourboulis et al\textsuperscript{69} studied blood samples from 53 patients with HS and six healthy controls. They found that the percentage of natural killer cells diminishes as time from initial skin lesions increases.\textsuperscript{69} They also found lower monocyte responses to bacterial components in patients with HS versus controls.\textsuperscript{69} The authors suggest this could be related to an autoimmune mechanism associated with HS, but recognize the need for more research to support their hypothesis.\textsuperscript{69}

Recently, a group of disorders characterized by noninfectious recurrent inflammatory episodes, the absence of autoantibodies and antigen-specific T cells, and the presence of polymorphonuclear cell infiltrates have been described. These disorders include familial Mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor–receptor-associated periodic syndrome, cryopyrin-associated periodic syndrome, pyogenic sterile arthritis, pyoderma gangrenosum, acne-like syndromes, recurrent multifocal osteomyelitis, CD, and Behçet disease. It is proposed that HS belongs to this group.\textsuperscript{70} Causes of the aforementioned disorders range from defects in inflammatory mediators and receptors to apoptosis.\textsuperscript{71–73} HS may share a similar defect.\textsuperscript{71}

Hunger et al\textsuperscript{74} investigated the roll of TLRs in HS using polymerase chain reaction studies and immunohistochemical staining. TLRs are expressed by inflammatory cells and play an integral role in innate immunity.\textsuperscript{74} They appear to be important in eliciting an immune response and in the release of proinflammatory cytokines.\textsuperscript{74} Compared with normal healthy volunteers, tissue specimens from HS patients show enhanced expression of TLR2 within macrophages and dendritic cells of inflammatory lesions of HS.\textsuperscript{74} Increased expression of these compounds has been found in other somewhat similar skin disorders, such as acne vulgaris.\textsuperscript{75}

**Pharmacologic factors.** Three reports of HS onset or exacerbation following initiation of lithium therapy suggest that HS may be a possible side effect of this agent.\textsuperscript{76–78} The suggested underlying cause is lithium’s ability to enhance neutrophil migration and phagocytic ability, increase epithelial cell proliferation, or its ability to cause follicular plugging through its direct effect on follicular keratinocytes (as in acne).\textsuperscript{76–78}

**Smoking.** Studies indicate an increased prevalence of smoking among patients with HS.\textsuperscript{19,28,79–81} Seventy percent to 88.9% of subjects in some published studies were smokers, suggesting that tobacco is a potential trigger for HS.\textsuperscript{70–81} A recent French study showed a strong association with current smoking in self-reported and medically assessed HS patients.\textsuperscript{19} However, this association did not exist for ex-smokers.\textsuperscript{19} Researchers have proposed that smoking may alter neutrophilic granulocytes (inducing altered chemotaxis), modify sweat gland activity, and give off toxic metabolites in sweat, all of which could explain this association.\textsuperscript{1,82} Parks and Parks\textsuperscript{27} believe that nicotine may eventually inhibit normal glandular secretions, subsequently plugging glandular ducts and ultimately producing an inflammatory reaction.\textsuperscript{27} However, at least one study fails to support this association.\textsuperscript{58}

**Obesity.** Much like smoking, there appears to be a relationship between obesity and HS.\textsuperscript{83} In a study by Rompel and Petres,\textsuperscript{80} 51.6% of subjects with HS were obese, with 21.5% being markedly obese. Harrison et al\textsuperscript{40} found that 77% of males with HS were overweight and 26% were obese, while 69% of females with HS were overweight and 33% were obese.\textsuperscript{40} Other studies have reported greater than 75% of HS patients to be obese.\textsuperscript{4,42} A significant association with body mass index in medically assessed HS patients was recently reported.\textsuperscript{19}

Obesity may aggravate disease in several ways through sweat retention and maceration, shearing of follicular or ductal outlets, and abnormal hormonal metabolism. In obese patients, the axilla is nested between the enlarged lateral thoracic wall and the upper arm, resulting in overlapping skin folds and subsequent friction, maceration, and occlusion of the skin.\textsuperscript{4} Shearing associated with increased skin-to-skin contact may trigger both follicular hyperkeratosis and follicular plugging via epidermal desquamation.\textsuperscript{1,4,9,15,17,30,46} Furthermore, the juxtaposition of skin surfaces may promote keratin hydration within sweat glands. This potentially reduces the diameter of the follicular orifice, further predisposing to poral occlusion.\textsuperscript{46} In addition, obesity has been associated with changes in the production, metabolism, and biologic activity of sex hormone binding globulin, androgens, and estrogens, causing a state of relative androgen excess. This androgen excess may result in coarsening of the hair shaft with subsequent follicular plugging.\textsuperscript{46}

**PSYCHOLOGICAL AND PHYSIOLOGIC MORBIDITY**

**Key points**

- HS patients experience a quality of life worse than those with alopecia, mild to moderate psoriasis, and several other dermatologic conditions
- HS results in economic and psychological disability in addition to the physical problems
von der Werth et al. measured morbidity in 114 HS patients using the DLQI questionnaire and demonstrated a total mean score of 8.9, which ranks above alopecia, mild to moderate psoriasis, and several other dermatologic conditions. This high score was heavily influenced by a question rating the level of pain, soreness, stinging, or itching. von der Werth et al. explain that the high total mean score is related to a combination of painful eruptions, malodorous discharge, stigma because of the location of lesions in intimate sites, and the lack of medical care related to incorrect diagnosis or the hesitancy of patients to disclose the symptoms or signs of HS.

Several studies have mentioned not only physical but also social and economic disabilities resulting from HS. One case report describes a 46-year-old male with painful draining abscesses of the buttocks, perineum, groin, and axillae, the malodorous discharge of which was so foul that he was forced to leave his job and was deserted by his family. Jemec et al. found that patients with HS lost an average of 2.7 work days per year because of HS. Among HS patients, females lost significantly more workdays than males, suggesting that females may have experienced more widespread or more severe disease. The number of births in females with HS was significantly less than in controls. The reason for this is unknown, but could be related to a reluctance of HS patients to participate in intimate activity.

A questionnaire that was distributed to 61 hospitalized HS patients revealed that their reported quality of life was worse than that of many other dermatologic diseases, such as chronic urticaria, psoriasis, atopic dermatitis, and even neurofibromatosis. The surveyed study population was comprised of hospital patients, so the study may not be representative of the overall HS population.

Self-reported health was significantly lower in HS patients compared to controls. Five of six patients in a study by Anderson et al. were unemployed, economically destitute, and either divorced or reclusive. Anderson and Perry have reported that, in addition to being unemployed and on welfare, many HS patients experience major personality changes, deterioration of the family unit, and may even commit suicide. They go on to state that patients “who are cured of chronic axillary hidradenitis are among the most grateful and appreciative patients one will encounter.”

DISEASE ASSOCIATIONS

Key point

• HS is associated with other diseases of the follicular occlusion tetrad, acne vulgaris, KID syndrome, IK, DDD, SAPHO syndrome, CD, Jackson–Lawler type pachyonychia congenital, reflex sympathetic dystrophy, and FFD, among others

HS has been associated with many disorders (Table III). The other disorders of follicular occlusion (acne conglobata, dissecting cellulitis of the scalp, and pilonidal cyst) are well known associations with HS, and make up the so-called follicular occlusion tetrad. A given patient may have two or more disorders within the tetrad. There may also be an association with acne vulgaris (30% in one study), which can be severe in chronic, generalized HS.

In separate studies by Mortimer et al., Brunsting, and Conway et al., 45%, 50%, and 70% of HS subjects, respectively, had associated acne vulgaris. Much like acral pustular psoriasis, there appears to be a strong association between obesity, smoking, and HS. These two associations were previously discussed at length. In summary, there are a high percentage of HS patients who smoke and/or are obese.

HS has been linked to several genetic disorders. Two case reports have described an association between keratitis-ichthyosis-deafness (KID) syndrome and HS. KID syndrome is caused by mutations in the connexin-26 gene. Connexin-26 is expressed most commonly on the palms and soles, but also on sweat glands and hair follicles. Hyperproliferative epidermis, resulting from the genetic defect, may predispose to follicular obstruction, with subsequent cyst formation, rupture, and secondary inflammation.

A single case series associating interstitial keratitis (IK) and HS exists. The authors performed a survey of 62 HS patients; in four patients, IK was discovered. HS preceded IK by a mean of 7.2 years. In all patients found to have IK, HS involved multiple sites with a degree of involvement ranging from moderately severe to very severe. These patients required numerous hospitalizations and surgical treatments for their HS. In addition, their ophthalmologic issues were severe and progressive, resulting in marked corneal destruction. The authors postulated that bacterial products within HS lesions might cause IK development related to a toxic reaction, allergic reaction, or endotoxin reaction.

At least eight reports have described the association of DDD and HS. DDD is a genetic syndrome characterized by acquired, reticulated, symmetrical pigmentary macules of the flexural areas. One report details the presence of HS and DDD in a mother and daughter. The authors propose that this association may be caused by a defect in follicular keratinization.
The association of HS, spondyloarthropathy, and acne conglobata is well described.104-112 This association is seen predominantly in African American males and equally affects the axial and appendicular joints. It has a chronic course, with temporal concurrence between cutaneous and arthritic flare-ups.106 Rosner et al109 suggest that the arthropathy may be a reaction to chronic skin infection. Others have suggested an association with human leukocyte antigen DR-4.112

SAPHO syndrome is an infrequently encountered heterogeneous skin–bone disease in which both osseous and articular manifestations occur along with skin manifestations.113,114 Most cases have been described in Japan, Scandinavia, Germany, and France.114 Kahn et al,115 Khan and Chamot,116 Chamot and Khan,117 and Khan118 have together proposed three diagnostic criteria for SAPHO syndrome: (1) multifocal noninfectious osteomyelitis, with or without skin manifestations; (2) sterile acute or chronic joint inflammation associated with (a) pustular psoriasis or palmoplantar pustulosis, (b) acne, or (c) HS; and (3) sterile mono- or polyosteitis in the presence of one of the aforementioned skin manifestations. According to Kahn et al115 and Khan and Chamot,116 any one of the above criteria is sufficient for a SAPHO diagnosis.

In one study, 12 patients with SAPHO from three hospitals were analyzed; seven had HS as part of their syndrome.114 All required extensive surgery for drainage and/or sweat gland resection and antibiotic and nonsteroidal antiinflammatory drug therapy.114 Of the seven patients with HS, six were African American, suggesting a possible SAPHO–HS predisposition in that population.114 The groin was affected in all seven patients and the axillae in six; two patients were affected perirectally and around the neck, and one had affected breasts.114 Three of the seven patients had pioderma gangrenosum and HS (associated with more aggressive SAPHO), three patients had life-threatening complications, including Gram-negative bacteremia, and two patients had a polyclonal gammopathy (associated with dense plasma cell infiltrates in skin and synovial biopsies).114 In addition, patients with the most severe HS had more erosive arthropathy.114 It appears that HS in the presence of SAPHO may be more deleterious than HS alone. Another seemingly related disease complex known as pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome has also been associated with HS.119

Several case reports and studies have suggested an association between HS and CD.28,120-122 In the largest of these reports, 24 of 61 (38%) HS patients also had a CD diagnosis. In most of these cases, CD affected only the large bowel, and its diagnosis preceded that of HS by 3.5 years; diagnosis of HS preceding that of CD has also been reported.120,122 HS affected the perineal and perianal area in all patients and secondary sites in 83% of patients.120 Perianal swelling and inflammation associated with CD may trigger development of perineal HS in those already at risk. Of course, this does not explain the frequent presence of axillary, groin, and buttoc disease.120

Todd et al123 reported five of six family members with Jackson–Lawler type pachyonychia congenita and concurrent HS. Pachyonychia congenita is an autosomal dominant genodermatosis affecting ectodermal development.124,125 The Jackson–Lawler subtype is characterized by natal teeth presence, steatocystoma multiplex, and multiple epidermoid cysts on the trunk, axillae, neck, and scalp, in addition to pachyonychia.124,125 The patients may also have palmar and plantar hyperkeratosis and blister development, hyperhidrosis, and follicular hyperkeratosis.124,125 Five of the six affected family members gave a history of recurrent abscesses in the axillae, groin, and anogenital areas.123 Three patients had evidence of scarring, nodules, and sinus tract formation in the axillae.123 Genetic, follicular, and/or inflammatory factors may explain the association.123

One report describes an association between reflex sympathetic dystrophy or complex regional pain syndrome type 1 and HS.126 The authors suggest HS as a consideration when searching for an etiology of new-onset reflex sympathetic dystrophy.126 Inflammatory stimulation may be a possible explanation for this association.126 More reports are necessary before one can put more confidence in this association.

Table III. Diseases associated with hidradenitis suppurativa

<table>
<thead>
<tr>
<th>Common associations</th>
<th>Rare associations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acne conglobata</td>
<td>Acanthosis nigricans</td>
</tr>
<tr>
<td>Acne vulgaris</td>
<td>Bazex-Dupre-Christol syndrome</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>Dowling–Degos disease</td>
</tr>
<tr>
<td>Dissecting cellulitis of the scalp</td>
<td>Fox–Fordyce disease</td>
</tr>
<tr>
<td>Obesity</td>
<td>Interstitial keratitis</td>
</tr>
<tr>
<td>Pilonidal disease</td>
<td>Keratitis-ichthyosis-deafness syndrome</td>
</tr>
<tr>
<td>Smoking</td>
<td>Pachyonychia congenita</td>
</tr>
<tr>
<td></td>
<td>PAPA syndrome</td>
</tr>
<tr>
<td></td>
<td>Pyoderma gangrenosum</td>
</tr>
<tr>
<td></td>
<td>Reflex sympathetic dystrophy</td>
</tr>
<tr>
<td></td>
<td>SAPHO syndrome</td>
</tr>
<tr>
<td></td>
<td>Scrotal elephantiasis</td>
</tr>
</tbody>
</table>

PAPA, Pyogenic arthritis, pyoderma gangrenosum, and acne; SAPHO, synovitis, acne, pustulosis, hyperostosis, and osteitis.
Lastly, Fox-Fordyce disease (FFD) is a rare pruritic disorder characterized by eruptions of small, discrete, flesh-colored papules located in the axillary, areolar, pubic, and sternal regions. Concurrent HS and FFD was described in three African American females. The authors attributed this association to follicular obstruction, which is present in both disorders.

PROGNOSIS AND DISEASE COMPLICATIONS

Key points

- The risk of SCC and other malignancies may be increased in those with HS
- Contractures, strictures, serious infection, and anemia are also potential sequelae

HS can cause significant complications (Table IV). There have been numerous reports that have associated HS with SCCs of the skin. The ratio of SCC in HS favors males (4:1). Sixty-one percent of cases were located in the perineum or buttocks; there were no reports of SCC in axillary HS. Forty-eight percent of these patients died within 2 years of SCC recognition. The mean duration of HS before SCC diagnosis was 25 years. A study of 125 patients with perianal or gluteal HS found that four (3.2%) of these patients had SCC; all four had HS for 19 years or longer. In another study, two of 64 (3.2%) perianal HS patients had evidence of SCC. The actual incidence of SCC in HS patients may be lower than these numbers suggest because of the selection bias inherent in these types of studies. In reporting two cases of anogenital verrucous carcinoma, Brown et al and Cosman et al proposed that human papillomavirus might be an important factor in the development of malignancy.

A large retrospective study with more than 2000 subjects revealed that those with HS had a 50% increased risk in overall incidence of malignancy. A 4.6-fold increase in cutaneous SCC was observed in these patients. Other significant malignant associations included buccal cancer and primary liver cancer, but Lapins et al explain that confounding by smoking and alcohol abuse may account for this.

The excessive scarring and fibrosis produced by HS lesions can lead to contractures and limitations in limb mobility, especially in the axilla. In addition, inflammation and scarring in the genitofemoral region may predispose to anal, urethral, and rectal strictures. Urethral fistulas and massive scrotal and vulvar lymphedema have also been reported in patients with HS. Anal fistulas are a consequence of longstanding perianal HS. Scarring and subsequent fixation of anal sphincters can potentially result in fecal incontinence.

There is a risk of serious infection depending on the location of lesions. One case describing a lumboSacral epidural abscess in a woman with a sacral decubitus ulcer caused by HS and another case of sacral bacterial osteomyelitis have been reported.

Finally, HS has been associated with anemia. A study by Tennant et al involving 42 consecutive cases of HS confirmed that 10 of these cases (23.8%) had marked anemia with hemoglobin levels below 10.0 g/100 cc; another 10 patients had milder anemia. All cases of marked anemia had severe HS of the buttocks and groin for more than 2 years. Tennant et al hypothesize that the anemia in HS is secondary to chronic infection. Many of the patients in this study also had elevated erythrocyte sedimentation rates and gamma-globulin. A report about one male who died from perineal/perianal HS complications described severe hypochromic anemia, hypoalbuminemia, hypergammaglobulinemia, amyloidosis, and fistulas to the rectum, urethra, urinary bladder, and peritoneum.

TREATMENT

Key points

- There is no uniformly effective single therapy for HS; therefore, clinicians will likely have to try an array of different treatment modalities depending on the patient’s disease
- For patients with extensive disease, wide excision can dramatically improve the patients’ quality of life
- Most of the listed therapies are ones that dermatologists possess intimate knowledge of and are thus in the best position to treat this debilitating disorder.

Antibiotics

Treatment for HS can be broadly grouped into either surgical or medical therapies. Antibiotic therapy for HS may be administered topically or systemically. Clindamycin is the best-studied of the topical medications. A randomized controlled trial
was conducted with 27 patients who used topical clindamycin 1% solution twice daily for 12 weeks. A randomized trial comparing topical clindamycin 1% solution twice daily to 500 mg of tetracycline twice daily was conducted by Jemec and Wendelboe. They found a significant abscess reduction occurred with both treatments during the first 3 months. More than 3 months were needed to appreciate nodule reduction. No significant difference in efficacy between topical clindamycin and oral tetracycline was demonstrated.

A small, uncontrolled, retrospective case series examining combination oral clindamycin and rifampicin found that 8 of 14 patients achieved 1- to 4-year long remissions after 10 weeks of combination therapy. Another two patients achieved remission after minocycline was substituted for clindamycin. Four patients discontinued therapy because of diarrhea.

Kaur and Lewis published a retrospective review of five patients treated with dapsone. They asked the patients to retrospectively complete a questionnaire regarding lesion soreness, frequency, and duration. They reported improvement in all five patients within 4 to 12 weeks of beginning therapy, at daily doses ranging from 25 to 150 mg. All patients required maintenance therapy between 50 and 150 mg daily. The median follow-up was 24 months. No patients had significant side effects. They hypothesize that dapsone works for HS as it does in other inflammatory dermatoses (ie, by inhibiting neutrophil chemotaxis). Though the number of good clinical studies is small, antibiotic therapy is, among almost all clinicians, the mainstay of initial therapy for HS.

**Retinoids**

Boer and van Gemert published a retrospective chart review of 64 patients treated with isotretinoin (mean dose, 0.56 mg/kg) for 4 to 6 months. Unfortunately, results were disappointing for a disease with a proposed pathogenesis similar to acne vulgaris. More than one quarter (29.4%) of patients did not complete the 4-month minimum study regimen. Patients mostly dropped out because of lack of efficacy, adverse side effects, or a combination of both. Less than one quarter (23.5%) of patients developed disease clearance; none of them, however, had severe disease at baseline. In 11 of 16 responders, positive results persisted for a mean of 57 months. The 32 patients with refractory disease were, justifiably, dissatisfied with therapy.

**Hormones**

Several trials using antiandrogen therapy have been conducted. In a randomized trial comparing ethinyloestradiol 50 mg/cyproterone acetate 50 mg to ethinyloestradiol 50 mg/norgestrel 500 mg in 24 patients, both regimens produced improvement in disease activity. Seven patients cleared with therapy, remaining disease-free 18 months posttreatment. In addition, five patients improved, four patients remained unchanged, and two patients worsened after treatment. There was no significant difference in treatment groups, with both regimens resulting in free androgen index reduction. Sawers et al published a case series examining four chronic HS patients receiving cyproterone acetate 100 mg daily. HS was controlled in all patients; disease worsened when the dosage was reduced to 50 mg daily. In a seven-patient trial examining the use of daily finasteride 5 mg (a type II 5-a-reductase inhibitor), complete healing of the lesions occurred in three patients; the remaining patients demonstrated reductions in suppuration and active inflammation. In two patients, disease remission occurred for 8 to 18 months following treatment discontinuation. Two patients developed HS recurrence 1 month posttreatment. One patient had bridging scars with recalcitrant pus pockets, prompting referral to surgery. Another patient discontinued therapy because of pruritus. Two patients in the study developed breast tenderness, one of which had persistent pain for a full year after discontinuing her medication.

A retrospective chart review of 64 females with HS found that the response to antihormonal therapy was superior to that of antibiotics (55% vs 25%). Of course, drawing conclusions from retrospective studies such as this should be done with caution.

**Immunosuppressive and antiinflammatory agents**

Immunosuppressive therapy has been used to target the inflammatory stages of HS. A patient with chronic granulomatous disease and HS who underwent a renal transplant experienced dramatic lesion improvement in the HS posttransplant. His medication regimen included prednisone 5 mg every other day, tacrolimus 1 mg daily, and mycophenolate mofetil 500 mg twice daily. Another case report detailed a male with intractable pyoderma gangrenosum and HS who was treated with cyclosporine 4.5 mg/kg/day. Both his pyoderma gangrenosum and HS dramatically improved. Other reports of patients taking cyclosporine have found similar improvements, but relapse tends to occur after drug
discontinuation.172 Another case report describes a patient with CD and HS treated with azathioprine, methylprednisolone, and isotretinoin.173 Both diseases went into remission following treatment. Jemec174 performed a study on three patients using 12.5 mg or 15 mg of methotrexate weekly for up to 6 months.174 No benefit was found.174

The TNF-alfa (TNFα) inhibitors infliximab and etanercept have also produced favorable outcomes in HS.170,121,130,160,175-190 Infliximab was first shown to be efficacious in HS patients with CD.189 A long-term study of 10 patients looking at efficacy of a single course of three infliximab infusions at 0, 2, and 6 weeks demonstrated improvement in all patients following therapy.176 The mean DLQI demonstrated improvement a year after initiating therapy as noted by their scores decreasing from 18.4 to 9.1.176 However, interpatient results varied markedly.176 Four patients had disease recurrence after 1 year, while two patients finished with scores only slightly below their pretreatment baseline.176 Brunasso et al191 recently reported long-term results in seven patients with a mean follow up of 119 weeks. They initially found impressive results 3 months after beginning therapy, with a mean pain reduction of 96.2%, a mean reduction of serous and purulent discharge of 69.5%, and a mean area reduction of 7%.191 Unfortunately, improvement began to decrease linearly over time, such that after 24 months, the mean pain reduction was 54.8%, the mean discharge reduction was 30.5%, and the mean area reduction was 1.25%.191 Other reports have described variable patient responses and significant adverse events, including lupus-like reactions, hypersensitivity reactions, abdominal pain secondary to colon cancer, multifocal motor neuropathy with conduction block, tuberculosis, and anaphylactic shock.170,180,181,188

Etanercept appears to have similar efficacy to infliximab, with the obvious advantage of subcutaneous injections instead of intravenous infusions. A study of six patients receiving etanercept 25 mg twice weekly demonstrated initial responses 16 days (mean) after therapy initiation.184 At 24 weeks post-initiation, mean self-reported DQLI scores improved by 64%.184 A single case report published by Zangrilli et al192 described improvement in a patient treated with etanercept that was measured by a self-reported DQLI and visual analogue pain score.192 The authors claimed the long-standing disease improvement occurred up to 48 weeks after the initiation of therapy; objective data from these claims, however, were not reported.192

Adalimumab, another TNFα inhibitor, has been documented as useful for HS treatment in two case reports. In one case, adalimumab 40 mg every other week successfully improved a patient with HS refractory to antibiotics, radiation therapy, and aggressive surgery.193 The patient experienced prompt improvement after one treatment; no long-term results were reported. The other report details a patient with seronegative arthritis and HS.194 He improved after 1 month of 40 mg injections every other week. After another month of treatment, the patient noted that his condition worsened; his dose was increased to 40 mg weekly. The patient’s pain and symptoms returned after he stopped the medication because of insurance issues.

There is not enough information available to assess the true risks of TNFα inhibitors used in HS patients. However, a metaanalysis of nine placebo-controlled trials using etanercept or adalimumab in patients with rheumatoid arthritis demonstrated significantly increased malignancies in those receiving high doses of medication (6 mg/kg of infliximab every 8 weeks or 40 mg of adalimumab every other week) than in those receiving low doses of medication (3 mg/kg of infliximab every 4 weeks or 20 mg of adalimumab weekly).195 Infusion-related reactions occur in up to 16% of patients receiving infliximab for psoriasis.196 These reactions include urticaria, pruritus, hypotension, and anaphylaxis.196 All TNFα inhibitors are associated with an increased risk of infection.196 Upper respiratory tract infections are the most common.196 Serious infections are uncommon, unless the patient is already predisposed because of preceding immune suppression.196 Nevertheless, they have been reported with the use of all TNFα inhibitors. Infections include mycobacterium tuberculosis, coccidioidomycosis, cryptococcosis, aspergillosis, listeriosis, candidiasis, pneumocystis, and histoplasmosis.196 Interestingly, these infections may be less common in those treated with etanercept rather than infliximab or adalimumab.197-199 Other problems, such as congestive heart failure exacerbation, lupus-like syndrome, hepatic disease, lymphoma, melanoma and nonmelanoma skin cancers, and hematologic disease have been reported.196

Other nonsteroidal antiinflammatory agents have been used in the treatment of HS. Most of these are supported only by anecdotal data, but among these there is particular enthusiasm for the use of oral zinc.200 Further studies are obviously necessary before a role for zinc or other nonsteroidal antiinflammatory drugs can be realistically determined.200 Corticosteroids also have a role to play in the treatment of HS. Publications detailing their use are sparse and often in combination with other medications.201-205 Corticosteroids are typically administered either intralesionally or orally.201-205 Dosing
regimens vary. Dramatic improvement may be seen initially, but their efficacy seems to be lost shortly after their discontinuation. They can be useful in treatment of flares, but their side effects limit long-term use.

**Neurotoxins**

A single case report has been published on the use of botulinum toxin for the treatment of HS. The authors performed a series of intradermal injections during a single treatment session. The patient’s inflammatory lesions resolved for 10 months following the treatment. The authors suggest that botulinum toxin may decrease apocrine gland secretion, thereby limiting tendency towards follicular rupture.

**Radiotherapy**

Radiation therapy for HS was extensively used in the past. Techniques and responses have varied widely. Radiotherapy has been suggested as efficacious for early lesions of HS but not for sinuses. In a study by Frohlich et al, 38% of patients treated had complete resolution of their symptoms. Forty percent more had clear improvement. Problems with poor tissue healing were noted. Zeligman reported that a single treatment with superficial x-rays was highly efficacious in his series of five patients. Hair follicle destruction is the suggested mechanism of action.

**Light, radiofrequency, and other procedures**

Cryosurgery has been studied as a potential HS treatment. Eight of 10 treated patients improved. Six patients developed infections and five developed ulcers. The average posttreatment healing time was 25 days. Carbon dioxide laser therapy has been used successfully in HS. Lapins et al treated 31 patients, reporting only four recurrences in targeted areas. However, 12 patients developed recurrences at sites more than 5 cm from the treatment area; 25 patients had recurrences at distant anatomic sites. Focused mode laser therapy was performed, and tissue was ablated at least until the subcutaneous plane. The procedure was similar to standard scalpel surgery in its endpoint.

Iwasaki et al published a case report of a 17-year-old male who responded well to three treatments with a nonablative radiofrequency device. His efficacy was based on a diary of daily symptoms. The patient noted an improvement in lesion number, quality, and duration. Peak improvement was noted 2 to 3 weeks following treatment. Six months after his third treatment, the patient continued to do well.

Photodynamic therapy has had mixed results. Gold et al noted a 75% to 100% improvement in four study patients. The last patient follow-up was 3 months posttreatment. No specific outcome measures were discussed in the paper. Rivard and Ozog reported two patients who improved with photodynamic therapy. Once again, no outcome measures were mentioned. Unfortunately, disease resumed in both patients following therapy. Strauss et al reported no improvement in four patients treated with photodynamic therapy; two had worsened 8 weeks posttreatment. Two patients—50% of the study population—dropped out before completing the study.

**Surgery**

Surgery is largely regarded as one of the most effective treatments for intractable HS. Surgery is largely regarded as one of the most effective treatments for intractable HS (Fig 7, 8, and 9). Surprisingly, this supposition lacks substantive randomized controlled trials. Treatment efficacy varies by location. A study of 82 patients with 118 radical excisions revealed recurrence rates of 0% in the perianal area and 5% in the axillary area. The inframammary and inguinoperineal areas, however, suffered from recurrence rates of 37% and 50%, respectively. Overall, 91% of patients were pleased with their results at follow-up. Unfortunately, 25% had recurrence of disease at a distant location. Operative complications occurred in 12% of subjects and included skin graft failure (45% of applied grafts), ischemic necrosis of a myocutaneous flap, limb vein thrombosis, anemia, transient edema, and hypertrophic scarring with pain requiring reoperation. A retrospective review of 72 patients found that recurrence rates were as high as 54% following excision down to fascia with primary closure. This figure dropped dramatically when flaps (19%) or split-thickness grafts (13%) were used for closure. Similar results were later reported by the same author examining another cohort of patients. Recurrence requiring reoperation after primary closure was 69.88% but was 0% for closure by flap and split-thickness graft, respectively. The lower recurrence rates with flaps and grafts probably reflect more extensive tissue removal than the particular closure techniques.

Ritz et al compared recurrence rates of HS after incision and drainage, limited excision, and radical wide excision. They found 100% recurrence after a median of 3 months in the drainage group, 42.8% recurrence in the local excision group (median time, 11 months), and 27% recurrence in the wide excision group (median time, 20 months).
A study comparing grafting to second intention healing following axillary excision of HS was performed in 10 patients with 20 treated axillas. The median time to complete healing was 7 weeks for the grafted sites and 12 weeks for the second intention sites. Seven of ten patients preferred the second intention healing method because of ease of use, limb mobility, lack of painful donor site, and comfort. Two patients preferred the more rapid healing of the graft site and one patient disliked both methods.

The laying open of sinus tracts, possibly as a staged procedure, is advocated by some as a compromise between the lack of efficacy of simple incision and drainage procedures or limited excision versus the morbidity of radical removal of all regional tissue. Evidence to support this supposition is limited to a single case series of four patients and a letter to the editor.

**APPROACH TO TREATMENT**

By this point, readers have likely come to understand the limited nature of clinical treatment trials that have been performed on patients with HS. There is no overwhelmingly effective treatment for patients with any stage of disease with HS. Therefore, most physicians will be forced to try a variety of different therapeutic modalities. We suggest a treatment algorithm based upon the Hurley classification or a tiered approach (Table V). Those with more severe disease may benefit from more aggressive therapy earlier than after a prolonged trial of less aggressive treatment modalities, or they may need multiple simultaneous treatment methods. It should be noted that the algorithm is not meant to suggest that patients with severe disease should not try one of the therapies listed for disease of more limited scope, but that more aggressive treatment might be helpful at the outset. Every patient is different and will require a unique approach depending on their disease and tolerance for risk. The scheme is also limited in that patients may not always fit exclusively into one Hurley stage, but the simplicity of the system should at least help the clinician formulate an initial approach to treatment.

For patients with abscesses, but no cicatrization or sinuses (Hurley stage I), antibiotics are a good first-line therapy. Limited lesions can be injected with corticosteroids, and flares can be addressed with short courses of oral or intramuscular corticosteroids. If this regimen is unsuccessful, zinc—or, if the patient is female and of nonchildbearing age, antiandrogen therapy—may be employed. If an insufficient response is obtained following these modalities, one of the other higher order methods may be chosen.

Patients with one or more widely separated recurrent abscesses with sinus tract formation and scars (Hurley stage II), or who have failed the first-line therapies, may need more aggressive treatment than those with early-stage lesions. Treatments that carry more risk may be worth trying depending on the severity of the patient’s disease course. Long-term immunosuppressive therapy or surgical therapies, such as limited excisions or the laying open of sinus tracts, may be helpful.
Patients with multiple interconnected sinus tracts and abscesses throughout an entire region (Hurley stage III) may have such debilitating disease that only surgery can adequately address their symptoms. Wide excision of all the patients’ affected tissue and the underlying sinus tracts is the most effective treatment for these patients. Though disease can recur in locations not treated by surgery and sometimes even within the treated area itself, almost all patients have substantial improvement following the procedure. Many methods have been discussed to close the wound, ranging from skin flaps, grafts, and even second intention healing. What matters most is that the diseased tissue is removed aggressively enough to minimize recurrence. For patients who may not want, or tolerate, a surgical procedure, one of the first- or second-tier therapies may be chosen (Table V).

In addition to the approach discussed above, there are recommendations that should be made to all patients regardless of their Hurley classification (Table VI). Because both smoking and obesity may play a role in the pathogenesis of HS, smoking cessation and weight loss should be encouraged. Avoidance of tight-fitting clothing has been suggested to help patients affected by HS. Support group referral is essential, because this can be a very embarrassing and debilitating disorder.

<table>
<thead>
<tr>
<th>Table V. Treatment suggestions for hidradenitis suppurativa based upon Hurley stage or initial therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hurley stage I disease or first-line therapy</strong></td>
</tr>
<tr>
<td>Antibiotics, either topical or systemic (A)</td>
</tr>
<tr>
<td>Hormonal therapy (A)</td>
</tr>
<tr>
<td>Retinoids (A)</td>
</tr>
<tr>
<td>Zinc (A)</td>
</tr>
<tr>
<td>Cryotherapy (B)</td>
</tr>
<tr>
<td>Botox (C)</td>
</tr>
<tr>
<td>Radiophotofrequency treatment (C)</td>
</tr>
<tr>
<td>Weight loss</td>
</tr>
</tbody>
</table>

Clinical recommendations are shown in parentheses after each table entry and are classified as follows: (A) recommendation based on consistent and good quality patient-oriented evidence; (B) recommendation based on inconsistent or limited quality patient-oriented evidence; and (C) recommendation based on consensus, opinion, or case studies.

<table>
<thead>
<tr>
<th>Table VI. General treatment suggestions for all hidradenitis suppurativa patients regardless of Hurley stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidance of tight-fitting clothing</td>
</tr>
<tr>
<td>Nonnarcotic analgesics</td>
</tr>
<tr>
<td>Reassurance</td>
</tr>
<tr>
<td>Smoking cessation</td>
</tr>
<tr>
<td>Stress management</td>
</tr>
<tr>
<td>Support group referral</td>
</tr>
<tr>
<td>Weight loss</td>
</tr>
</tbody>
</table>

CONCLUSION

The prevalence of HS may equal or even surpass that of psoriasis, yet it receives only a fraction of the attention and scholarly contributions. Though no overwhelmingly effective treatments have been described, novel therapies are emerging. Many—if not all—of these therapies are well known to dermatologists; therefore, we should play a lead role in managing this debilitating disorder. As our understanding of this disorder grows, so will our treatment options. Readers may find the book by Jemec et al224 helpful.

We thank Maxwell A. Fung, MD, for writing the histopathologic description for Fig 6; Steven R. Feldman, MD, and Megan Kinney, BS, for providing the pathologic image; Hope Haefner, MD, and Michael S. Wong, MD, for providing some of the clinical images; and Miki Garcia, MD, for her work editing the manuscript.

REFERENCES


